SCHEDULE 13G/A: KCK Ltd. Discloses 17.7% Beneficial Ownership in NeuroPace Inc.

KCK Ltd. has filed an amended Schedule 13G, revealing a 17.7% beneficial ownership stake in NeuroPace Inc.'s common stock as of December 31, 2024.

Summary

• KCK Ltd., a Bermuda-based entity, reported beneficial ownership of 5,270,845 shares of NeuroPace Inc. Common Stock.
• This ownership represents 17.7% of NeuroPace Inc.'s outstanding Common Stock.
• The percentage is calculated based on 29,848,101 shares of Common Stock outstanding, as reported in NeuroPace Inc.'s Form 10-Q filed on November 12, 2024.
• KCK Ltd. holds both sole voting power and sole dispositive power over all 5,270,845 shares.
• The filing is an Amendment No. 3 to a Schedule 13G, indicating an update to a previously reported beneficial ownership position.
• The event requiring this filing occurred on December 31, 2024.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership, not a performance report or strategic announcement, thus it carries a neutral sentiment.

Industry Context

This Schedule 13G filing indicates a significant beneficial ownership stake by KCK Ltd. in NeuroPace Inc., a company operating in the medical device sector. Such filings are standard disclosures required by the SEC when an entity acquires more than 5% of a company's outstanding shares, providing transparency on major shareholders.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional investor's stake, potentially influencing market perception and trading activity.
• Company Management: Awareness of a large, concentrated ownership position, which may lead to increased engagement or influence from the beneficial owner.

Key Dates

Keywords

NeuroPace Inc, KCK Ltd., Beneficial Ownership, Schedule 13G, Common Stock, SEC Filing, Institutional Ownership, Equity Stake, Medical Devices